Adicet Bio, Inc. Retained Earnings
Adicet Bio, Inc. (ACET) had Retained Earnings of -$656.30 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$656.30M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$634.94M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$614.70M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$584.18M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$656.30M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$634.94M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$614.70M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | -$584.18M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$557.33M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$526.11M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | -$497.89M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$469.17M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | -$438.69M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$408.79M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$380.77M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$351.28M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$301.40M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$269.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$238.11M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$208.24M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$186.24M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | -$163.71M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$168.32M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$152.51M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$138.50M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$127.64M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$106.33M 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$97.37M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$166.77M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | -$161.17M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$69.65M 10-K · filed 2021-03-12 | -$154.13M 10-K · filed 2020-03-12 |
| 2019-09-30 | -$125.24M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | -$100.79M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$82.46M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$71.39M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$65.64M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$57.23M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$43.64M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$33.78M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |